Premium
RITUXIMAB, LENALIDOMIDE, AND IBRUTINIB ALONE AND COMBINED WITH CHEMOTHERAPY FOR PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B ‐CELL LYMPHOMA
Author(s) -
Westin J.R.,
Fayad L.,
Oki Y.,
Nastoupil L.,
Hagemeister F.,
Turturro F.,
Lee H.J.,
Rodriguez A.,
Young K.H.,
McDonnell T.,
Ford R.,
Neelapu S.,
Davis R.E.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_51
Subject(s) - medicine , lenalidomide , rituximab , ibrutinib , diffuse large b cell lymphoma , chemotherapy , oncology , lymphoma , chemotherapy regimen , febrile neutropenia , neutropenia , surgery , gastroenterology , multiple myeloma , leukemia , chronic lymphocytic leukemia
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom